SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors
January 26 2017 - 9:05AM
— Former Chief Operating Officer of Medivation adds broad
experience in commercial, strategy, operations and business
development —
SCYNEXIS, Inc. (Nasdaq:SCYX), a pharmaceutical company developing
novel anti-infectives to address unmet therapeutic needs, today
announced the appointment of Marion McCourt to its Board of
Directors. Ms. McCourt most recently served as Chief Operating
Officer of Medivation, Inc., a biopharmaceutical company focused on
the development and commercialization of medically innovative
therapies to treat serious diseases for which there are limited
treatment options, until the acquisition of Medivation by Pfizer in
September 2016. The appointment expands the SCYNEXIS Board to eight
members.
"Marion brings diverse operational and commercial expertise to
the SCYNEXIS Board as we prepare to advance our promising lead
anti-fungal candidate, SCY-078, into later-stage trials and
commence pre-commercial activities,” said Guy Macdonald, Chairman
of the Board of SCYNEXIS. "On behalf of my fellow Board members, I
would like to welcome Marion and look forward to her contributions
and expertise as we carry out the important work of bringing novel
antifungal treatments to patients."
"2016 was a successful year for our company, and given our
recent clinical progress with SCY-078, the addition of Marion’s
commercial, marketing and reimbursement expertise to our Board will
serve us well," said Marco Taglietti, M.D., President and Chief
Executive Officer of SCYNEXIS. "We are privileged to have Marion
join us at this important time in our evolution, and we are eager
to leverage her insights and guidance as we continue to advance the
development of SCY-078 in multiple indications and to expand our
business development activities."
“It has been many years since significant advancements have been
made in the fight against invasive fungal infections, and growing
resistance to current treatment alternatives is quickly emerging as
a global public health crisis,” said Ms. McCourt. “I am impressed
by SCYNEXIS’ progress to date, and I believe that SCY-078 has the
potential to address significant unmet medical needs. I am honored
to join such an impressive team of executives and directors, and I
look forward to contributing to the Company’s future
success.”
Ms. McCourt brings to the SCYNEXIS Board more than two decades
of wide-ranging leadership experience at several of the world's
most respected and innovative biopharmaceutical companies. Prior to
joining Medivation as Chief Operating Officer in February 2016, Ms.
Marion served as Vice President of U.S. Commercial Operations at
Amgen Inc. (NASDAQ:AMGN), one of the world's leading independent
biotechnology companies. Prior to that, she also served as Vice
President and General Manager of Amgen’s Bone Health & Primary
Care Business Unit. Before joining Amgen, Ms. McCourt held numerous
positions of increasing responsibility over a twelve-year career at
AstraZeneca (NYSE:AZN) in the U.S. and Canada. There, she
ultimately achieved the title of Chief Operating Officer of
AstraZeneca U.S. where she was responsible for all U.S. commercial
functions, including medical affairs, business development,
finance, human resources, legal, operations, and corporate affairs.
Ms. McCourt holds a B.S. degree in Biology from Lafayette
College.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the
development and commercialization of novel anti-infectives to
address significant unmet therapeutic needs. We are developing our
lead product candidate, SCY-078, as an oral and IV drug for the
treatment of several fungal infections, including serious and
life-threatening invasive fungal infections. For more information,
visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding matters
that are expected to occur in the future are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to: SCYNEXIS’s
plan to advance SCY-078 to the next stages of development
in 2017. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited, to: risks
inherent in SCYNEXIS' ability to successfully develop SCY-078,
including SCYNEXIS' ability to obtain FDA approval for SCY-078; the
expected costs of studies and when they might begin or be
concluded; and SCYNEXIS' reliance on third parties to conduct
SCYNEXIS' clinical studies. These and other risks are described
more fully in SCYNEXIS' filings with the Securities and Exchange
Commission, including without limitation, its most recent Annual
Report on Form 10-K under the caption "Risk Factors" and other
documents subsequently filed with or furnished to the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. SCYNEXIS undertakes no obligation to update such statements
to reflect events that occur or circumstances that exist after the
date on which they were made.
CONTACT:
Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781.235.3060
cduong@macbiocom.com
Investor Relations
Susan Kim
Argot Partners
Tel: 212.203.4433
susan@argotpartners.com
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024